Natco Pharma promoter Durga Devi Nannapaneni gifted 50,000 equity shares of the company to her niece, G. Kalajyothi. The off-market transaction was executed on August 24, 2026.

The company disclosed the transfer under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and Regulation 7(2) read with Regulation 6(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015. The filing was submitted to the BSE and NSE on August 26, 2026.

Shareholding Changes

Prior to the gift, Nannapaneni held 35,39,100 shares, representing a 1.98% stake in the company. Following the disposal, her holding reduced to 34,89,100 shares, or 1.95% of the total voting capital. The total diluted share capital of Natco Pharma remained unchanged at 17,91,09,870 shares.

Regulatory Compliance

The disclosure confirms that no derivatives were traded by the promoter in connection with this transaction. The mode of acquisition for the recipient was specified as an off-market gift. No pledge or encumbrance details were reported for the transferred shares.

Natco Pharma has invested an additional $14 million in Egenesis, Inc. via its subsidiaries, raising its total investment in the US-based biotech firm to $22 million. The latest tranche was executed through convertible promissory notes, marking a shift from the equity structure of its prior investment.

Investment details

The incremental investment was made through Natco Pharma's wholly owned subsidiaries, NATCO Pharma (Canada) Inc. and NATCO Pharma South Africa Proprietary Limited. Unlike the previous investment made in 2024, which involved preferred stock, this round utilizes debt instruments with conversion options.

The following table summarises the key parameters of the new investment:

About Egenesis

Egenesis, Inc. is a biotechnology company focused on creating transplantable organs through genome engineering. The company applies genetic modification techniques to develop organs intended for human transplantation, addressing a critical area within regenerative medicine.

In March 2024, eGenesis announced the world's first porcine kidney transplant in a living patient, authorized by the US FDA under the Expanded Access pathway. This was followed by two additional porcine kidney transplants with positive outcomes. The company continues to advance development programs for kidney transplant, acute liver failure, and heart transplant using its EGEN platform.